Inclusion Criteria:

- Histologically confirmed inoperable (stage IIIB-IV) NSCLC. A block of Formaline Fixed
Parafine Embedded tissue representative for the primary diagnosis should be available
for genomic analysis (phase II part)

- Written informed consent

- Prior chemotherapy with platinum compounds in association with or without taxanes
(phase I part)

- Previously untreated with docetaxel and pemetrexed (phase II part)

- Bidimensionally, non-irradiated measurable disease (according to RECIST criteria)
(phase II)

- Age ≥18 years

- World Health Organization (WHO) performance status (PS) 0-2

- Life expectancy of at least 12 weeks

- Serum bilirubin less than 1.5 times the upper normal limit (UNL)

- AST and ALT less than 2.5 times the UNL in the absence of demonstrable liver
metastases, or less than 5 times the UNL in the presence of liver metastases.

- Serum creatinine less than 1.5 times the UNL

- Neutrophil count more than 1.5x 109 /L

- Platelet count more than 100x 109 /L

Exclusion Criteria:

- Other co-existing malignancies or malignancies diagnosed within the last 5 years
(with the exception of basal cell carcinoma or cervical cancer in situ)

- Any evidence of severe uncontrolled concomitant disease (in the opinion of the
investigator)

- Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer
therapy

- Patients with unstable central nervous system metastases

- Malnutrition (loss of ≥ 20% of the original body weight)

- Performance status: 4

- Psychiatric illness or social situation that would preclude study compliance

- Pregnant or lactating women